Phase 3b Trial Registered Comparing Povetacicept Autoinjector Experience With Sibeprenlimab Prefilled Syringe in IgAN
Start here
A Phase 3b study of povetacicept in IgA nephropathy has been registered to compare the participant experience of povetacicept administered via autoinjector against sibeprenlimab given via prefilled syringe. The trial, registered under NCT07890909, plans to enroll 40 participants and will also assess the safety and tolerability of povetacicept. The study is not yet recruiting and has a planned start date of 2026-10-23. Questions that remain open include when recruitment will actually begin, what the participant-experience endpoints will show, and how the autoinjector's usability compares with the prefilled syringe format in practice.
Written by a model from the reports · updated 2 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- clinicaltrials.govPickA Phase 3b Study of Participant Experience on Povetacicept Administered Via Autoinjector as Compared to Sibeprenlimab Administered Via Prefilled Syringe
A Phase 3b study of povetacicept in IgAN has been registered, comparing the treatment experience of its autoinjector with sibeprenlimab prefilled syringe. The trial plans to enroll 40 participants and will assess the safety and tolerability of povetacicept. NCT07890909 was first registered on 2026-10-22, is not yet recruiting, and is planned to start 2026-10-23.
Heat trend for this story
Not enough continuous observation yet to draw a trend.